EGFR and glioblastoma: The 2021 WHO classification accounts for these new insights by stipulating molecular criteria that allow for a diagnosis of GBM, CNS WHO grade IV, in IDH‐wildtype astrocytomas, even in the absence of high‐grade histopathologic features, when at least one of the following molecular features is present: TERTp mutation, EGFR amplification, or concurrent +7/−10.5